Sign In
Buy CRL
$179.87
+5.08 (+2.91%)
At Close: Jun 03, 2026
CRL Gears Up for Q3 Earnings: Here's What You Need to Know
10:30am, Tuesday, 22'nd Oct 2024
Growth across all businesses within the Manufacturing segment is likely to have contributed to Charles River's Q3 revenues, offset by lower biopharmaceutical demand.
CRL Stock Gains From New Retrogenix Non-Human Protein Library Launch
09:55am, Friday, 18'th Oct 2024
Charles River launches Retrogenix Non-Human Protein Library to provide early insights into how therapeutics interact with non-human protein targets in vitro.
Charles River Launches New Retrogenix® Non-Human Protein Library
08:00am, Thursday, 17'th Oct 2024
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River launches the Retrogenix® Non-Human Protein Library to support assessment of off-target binding, de-risk studies & aid model selec
Charles River Laboratories Schedules Third-Quarter 2024 Earnings Release and Conference Call
04:30pm, Wednesday, 16'th Oct 2024
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories schedules third-quarter 2024 earnings release and conference call.
CRL to Aid Lundbeck's Neurological Drug Research With AI-Backed Logica
10:10am, Thursday, 10'th Oct 2024
Charles River and Lundbeck sign an agreement to use Logica to advance the discovery of novel neurological drugs.
Operadora de Fondos Banorte Adopts Charles River's Cloud-Based Platform
11:26am, Tuesday, 08'th Oct 2024
BOSTON--(BUSINESS WIRE)--Banorte is now live on Charles River's cloud-based Investment Management Solution.
Xspray Pharma Announces Positive FDA Meeting and Plans for Dasynoc NDA Resubmission
06:00am, Thursday, 19'th Sep 2024
STOCKHOLM--(BUSINESS WIRE)--Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY), a pharmaceutical company leveraging its proprietary HyNap™ technology to develop enhanced cancer therapies, today anno
CRL Stock to Gain From Strategic Neuroscience Partnership With CEBINA
09:11am, Wednesday, 18'th Sep 2024
Charles River collaborates with CEBINA as part of the DanubeNeuro program to advance innovation in neurodegeneration.
Ori Biotech and Charles River Laboratories Collaborate to Accelerate Life-Saving Cell and Gene Therapy Development and Manufacturing
08:30am, Wednesday, 18'th Sep 2024
New Biological Data Released from IRO® Cell Therapy Manufacturing Platform New Biological Data Released from IRO® Cell Therapy Manufacturing Platform
CRL Stock May Benefit From New Neuroscience Research Collaboration
10:30am, Monday, 09'th Sep 2024
Charles River's new alliance with Insightec to advance therapeutic development using focused ultrasound in neuroscience.
Why Is Charles River (CRL) Down 5.3% Since Last Earnings Report?
12:37pm, Friday, 06'th Sep 2024
Charles River (CRL) reported earnings 30 days ago. What's next for the stock?
SAN DIEGO, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP (www.johnsonfistel.com), a shareholder rights law firm, announces its continuing investigation of whether certain directors and officer
Charles River Laboratories: Changing Economics Reduces Compounding Ability (Rating Downgrade)
06:31am, Thursday, 15'th Aug 2024
Charles River came in with another set of soft numbers, indicating a period of weaker business ahead for the company. Management is scaling back CapEx into the business and focusing on buybacks, sugge
NEW YORK, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Charles River Laboratories Inter
Why Charles River (CRL) International Revenue Trends Deserve Your Attention
10:21am, Monday, 12'th Aug 2024
Examine Charles River's (CRL) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.
